- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT03986021
Maturação do eixo reprodutivo nos primeiros anos pós-menarca
Maturação do eixo reprodutivo nos primeiros anos pós-menarca: um estudo piloto
Background:
Most adult women with irregular periods of unknown cause report symptoms dating back to early adolescence. This study aims to learn how girls' periods change in the 2 years after their first period. We are also looking at girls who may have a condition called PCOS. This will help researchers learn what healthy puberty looks like and how they can spot signs of hormone problems early on.
Objective:
To learn how long it takes girls to develop regular menstrual cycles after their first period.
Eligibility:
Healthy girls ages 8-14 who either (1) haven't had their first period but show signs of puberty, such as breast development and hair in the genital area; or (2) had their first period in the past 6 months
Girls at risk for PCOS age 8-14 who have a mom or sister with PCOS
Girls with irregular menstrual cycles age 11-17.5
To compare with the girls, we are looking at women >=18-34 years old with PCOS,
Healthy women >= 18-34 years old without PCOS,
and Mothers of pediatric participants age 18-65
Design:
Both parents or guardians must allow their daughter to participate. They must attend all study visits with her.
Participants will first be screened by phone. Those who qualify will be screened in person. They will have a physical exam. They will give blood and urine samples. They will have an ultrasound of their abdomen. They will fill out questionnaires. They will sit in a BOD POD for 6 minutes: This is an egg- shaped machine that takes body measurements. They have the option to provide DNA samples.
Participants will have sets of visits at home or at the clinic about every 6 months. The number of visits in each set will depend on their menstrual cycle. Then they will have a final visit. Visits will include repeats of the screening tests. There are additional parts that participants may choose to be involved in depending on how involved they want to be.
At home, participants will collect their urine daily to measure hormones. They will keep a diary of their periods.
Adults: Women with known PCOS will complete the same Screening Visit as the girls and will collect dried urine specimens at home for 8 weeks;
The Healthy control women group will complete the same Screening Visit as the girls and collect dried urine specimens at home for 2 menstrual cycles;
The Mothers of pediatric participants group will complete a Screening Visit (informed consent, urine pregnancy test) and collect vaginal swab specimens at home for 2 menstrual cycles (approx. 8 weeks).
Visão geral do estudo
Status
Descrição detalhada
The broad goal of these studies is to determine the physiologic and pathophysiologic underpinnings of irregular menstrual cycles among adolescents in general and those with increased genetic risk for polycystic ovarian syndrome (PCOS) in the early postmenarchal
period. Irregular menstruation affects > 2.5 million reproductive-age women in the US each year1. Most adult women with oligomenorrhea of unknown etiology reporting symptoms dating back to early adolescence. Importantly, irregular menstrual cycles during the teenage years may be a harbinger of future health risks extending beyond the reproductive system; among the nearly 80,000 female participants the Nurses' Health Study II, those with irregular and long cycles during adolescence and adulthood had a greater risk of premature mortality, particularly related to cardiovascular disease. While a period of cycle irregularity is well-described in the first few years after menarche, a lack of understanding of the basic mechanisms of normal reproductive axis development in the post-menarchal female has hampered our ability to distinguish abnormal from normal developmental trajectories. Moreover, the commonly held belief that menstrual irregularity among teenage girls is normal has also delayed detection of pathology in reproductive development, precluding institution of early preventative strategies to curtail future reproductive morbidity.
Tipo de estudo
Inscrição (Estimado)
Contactos e Locais
Contato de estudo
- Nome: NIEHS Join A Study Recruitment Group
- Número de telefone: (855) 696-4347
- E-mail: myniehs@nih.gov
Estude backup de contato
- Nome: Natalie D Shaw, M.D.
- Número de telefone: (984) 287-3716
- E-mail: natalie.shaw@nih.gov
Locais de estudo
-
-
North Carolina
-
Research Triangle Park, North Carolina, Estados Unidos, 27709
- Recrutamento
- NIEHS Clinical Research Unit (CRU)
-
Contato:
- NIEHS Join A Study Recruitment Group
- Número de telefone: 855-696-4347
- E-mail: myniehs@nih.gov
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
Healthy early post-menarchal girls age 8-<15 years; PCOS women and girls with first degree relatives with PCOS; Healthy women 18-34 years; Late post-menarchal girls age 11-<17.5; healthy pre-menarchal girls age 8-<14.5; mothers of pediatric participants age 18-65
Descrição
- Part 1 - Pre-menarche monitoring ("holding pattern"):
Inclusion Criteria:
- Age 8-14.5 years old
- Healthy weight, defined as having a body weight >85% of expected (EBW) and a body mass index (BMI) <99th percentile
- Some breast development
- Pre-menarche
Exclusion Criteria:
- Taking or planning to take medications that affect reproductive hormones in the next 2 to 3 years (e.g. birth control pills, biotin supplements).
- Planning to move more than 60 miles from the CRU within the next 2 to 3 years
- Chronic medical condition, including but not limited to diabetes mellitus, congenital adrenal hyperplasia, cystic fibrosis, sickle cell disease, inflammatory bowel disease, juvenile rheumatoid arthritis, and lupus.
- First-degree relative with polycystic ovarian syndrome, premature ovarian insufficiency, hypogonadotropic hypogonadism, or other pubertal development disorder
- Excessive exercise (defined as running >20 miles per week or its equivalent)
- Pregnancy
Part 2 - Post-menarche cycle tracking:
Inclusion Criteria:
- Age at menarche 10-14.5 years old
- Healthy weight, defined as having a body weight >85% of expected (EBW) and a body mass index (BMI) <99th percentile
- Approximately < 6 months post-menarchal (will typically have completed 4 or fewer menstrual cycles)
- Biochemical criteria: normal thyroid hormone, prolactin, and testosterone levels
Exclusion Criteria:
-
Taking or planning to take medications that affect reproductive hormones in the next 2 to 3 years (e.g. birth control pills, biotin supplements).
-
Planning to move more than 60 miles from the CRU within the next 2 to 3 years
-
Chronic medical condition, including but not limited to diabetes mellitus, congenital adrenal hyperplasia, cystic fibrosis, sickle cell disease, inflammatory bowel disease, juvenile rheumatoid arthritis, and lupus.
-
First-degree relative with polycystic ovarian syndrome, premature ovarian insufficiency, hypogonadotropic hypogonadism, or other pubertal development disorder
-
Excessive exercise (defined as running >20 miles per week or its equivalent)
-
Anemia (defined as hemoglobin <12.0 g/dl)
--Participants with hemoglobin between 11.5 g/dl and 12.0 g/dl may still participate by providing dried blood spots, or no more than 18 ml of blood during any given interval.
-
Pregnancy
Part 3 - Intensive monitoring of ovarian follicle growth
Inclusion Criteria:
- Age at menarche 10-14.5 years old
- Healthy weight, defined as having a body weight >85% of expected (EBW) and a body mass index (BMI) <99th percentile
- Within 1 year of menarche
- Biochemical criteria: normal thyroid hormone, prolactin, and testosterone levels
Exclusion Criteria:
-
Taking or planning to take medications that affect reproductive hormones in the next 1-2 years (e.g. birth control pills, biotin supplements).
-
Planning to move more than 60 miles from the CRU within the next year
-
Chronic medical condition, including but not limited to diabetes mellitus, congenital adrenal hyperplasia, cystic fibrosis, sickle cell disease, inflammatory bowel disease, juvenile rheumatoid arthritis, and lupus.
-
First-degree relative with polycystic ovarian syndrome, premature ovarian insufficiency, hypogonadotropic hypogonadism, or other pubertal development disorder
-
Excessive exercise (defined as running >20 miles per week or its equivalent)
-
Anemia (defined as hemoglobin <12.0 g/dl)
--Participants with hemoglobin between 11.5 g/dl and 12.0 g/dl may still participate by providing dried blood spots, or no more than 18 ml of blood during any given interval.
-
Pregnancy
Part 4 - Late Post-menarche cycle tracking:
Inclusion Criteria:
- Age 11-17.5 years old
- Approximately 2-5 years post-menarchal
- Biochemical criteria: normal thyroid hormone and prolactin
Exclusion Criteria:
-
Taking or planning to take medications that affect reproductive hormones in the next 2 to 3 years (e.g. birth control pills, biotin supplements).
-
Planning to move more than 60 miles from the CRU within the next 6 months
-
Chronic medical condition, including but not limited to diabetes mellitus, congenital adrenal hyperplasia, cystic fibrosis, sickle cell disease, inflammatory bowel disease, juvenile rheumatoid arthritis, and lupus.
-
Anemia (defined as hemoglobin <12.0 g/dl)
--Participants with hemoglobin between 11.5 g/dl and 12.0 g/dl may still participate by providing dried blood spots, or no more than 18 ml of blood during any given interval.
-
Pregnancy
Adolescent girls, at-risk daughters, or sisters of women with PCOS
The girls with mothers or sisters with PCOS group will complete the Screening Visit and Parts 1-3. The same inclusion and exclusion criteria apply for Parts 1, 2, and 3 as stated above except that these individuals must have a first-degree relative with PCOS and they can have high androgen levels, excess body hair, and severe acne at screening.
Women with known PCOS (activities for 8 weeks only)
Inclusion Criteria:
- Age >=18-34 years old
- PCOS diagnosis
- at least 3-years post-menarchal with irregular menstrual cycles
- Biochemical (blood) or clinical signs of high androgen levels
Exclusion Criteria:
- Cannot be taking any medications that affect reproductive or metabolic hormones (e.g. birth control pill, biotin supplements, spironolactone, metformin).
- Chronic medical condition, including but not limited to diabetes mellitus, congenital adrenal hyperplasia, cystic fibrosis, sickle cell disease, inflammatory bowel disease, juvenile rheumatoid arthritis, and lupus.
- Pregnancy
Healthy control women (Activities for 2 menstrual cycles)
Inclusion Criteria:
- Age >=18-34 years old
- at least 3-years post-menarchal with regular menstrual cycles every 21-35 days
Exclusion Criteria:
- Cannot be taking any medications that affect reproductive or metabolic hormones (e.g. birth control pill, biotin supplements, spironolactone, metformin).
- Chronic medical condition, including but not limited to diabetes mellitus, congenital adrenal hyperplasia, cystic fibrosis, sickle cell disease, inflammatory bowel disease, juvenile rheumatoid arthritis, and lupus.
- PCOS diagnosis or first-degree relative with disorder
- Pregnancy
Mothers of pediatric participants (Activities for 8 weeks / 2 menstrual cycles)
Inclusion Criteria:
- Age >=18-65 years old
- Biological mother of A Girl's First Period participant
Exclusion Criteria:
- Chronic medical condition, including but not limited to diabetes mellitus, congenital adrenal hyperplasia, cystic fibrosis, sickle cell disease, inflammatory bowel disease, juvenile rheumatoid arthritis, and lupus.
- Pregnancy
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Modelos de observação: COHORT
- Perspectivas de Tempo: PROSPECTIVE
Coortes e Intervenções
Grupo / Coorte |
|---|
|
At-risk girls
Girls with first degree relative diagnosed with Polycystic Ovary Syndrome (PCOS) age 8-<15 |
|
early post-menarche girls
Healthy, early post-menarchal girls age 8-<15 |
|
Healthy control women
Women age >18-34 without PCOS at least 3-years post-menarchal with regular menstrual cycles every 21-35 days |
|
late post-menarche girls
Late post-menarchal girls age 11-<17.5 (gynecological age 2-5) |
|
Mothers of pediatric study participants
Mothers age 18-65 whose daughter has provided at least one vaginal swab sample for the First Period study. |
|
pre-menarche girls
Healthy, pre-menarchal girls age 8-<14.5 |
|
Women with PCOS
Women diagnosed with PCOS >18-34 at least 3-years post-menarchal with irregular menstrual cycles |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
To determine the time from menarche to regular ovulatory cycles, defined as two consecutive ovulatory cycles in girls of variable genetic risk for PCOS
Prazo: Defined as two consecutive ovulatory cycles with normal (10-14 day) luteal phase length during the first two post-menarchal years
|
We hypothesize that the temporal sequence of reproductive maturation will consist of anovulatory cycles (representing a time of unopposed estrogen exposure), ovulatory cycles with a short luteal phase (estrogen with low progesterone exposure), and finally, ovulatory cycles with a normal luteal phase length (estrogen action fully counterbalanced by progesterone action) |
Defined as two consecutive ovulatory cycles with normal (10-14 day) luteal phase length during the first two post-menarchal years
|
Colaboradores e Investigadores
Investigadores
- Investigador principal: Natalie D Shaw, M.D., National Institute of Environmental Health Sciences (NIEHS)
Publicações e links úteis
Links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Outros números de identificação do estudo
- 190110
- 19-E-0110
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
It is not yet known if there will be a plan to make IPD available
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .